NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant drop in short interest in December. As of December 15th, there was short interest totaling 9,001 shares, a drop of 15.5% from the November 30th total of 10,658 shares. Based on an average trading volume of 3,722 shares, the days-to-cover ratio is currently 2.4 days. Based on an average trading volume of 3,722 shares, the days-to-cover ratio is currently 2.4 days.

NeuroSense Therapeutics Trading Down 18.0%

NeuroSense Therapeutics stock opened at $0.32 on Friday. The stock has a 50 day moving average of $0.36 and a 200-day moving average of $0.49. NeuroSense Therapeutics has a 52 week low of $0.12 and a 52 week high of $1.06.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.